In a cancer- wide genome analysis of prognostic gene signatures, KLRB1, the gene encoding CD161, was identified as most frequently associated with favorable outcomes against several indications including bladder, breast, colon, prostate cancers, melanoma, lung adenocarcinoma, multiple myeloma, glioma, and neuroblastoma to name a few (72, 73). Here, KLRB1 is linked to plasma cell myeloma.